期刊文献+

双吗啉类PI3Kα抑制剂的自组织分子场分析

Self-organizing molecular field analysis on PI3Kα inhibitors:dimorpholino derivatives
下载PDF
导出
摘要 采用自组织分子场分析(SOMFA)构建了39个双吗啉类磷脂酰肌醇-3激酶α(PI3Kα)抑制剂的三维定量构效关系模型。交叉验证相关系数(q2)、非交叉验证相关系数(r2)、标准偏差(SEE)分别为0.636、0.702和0.581,立体场和静电场的贡献分别为0.7和0.3,并用测试集进行了验证。测试集非交叉验证相关系数(r2pred)为0.808。该模型具有显著的统计学意义,为进一步开发新的双吗啉类PI3Kα抑制剂奠定了基础。 To study the three-dimensional quantitative-structure activity relationship (3D-QSAR) of 39 dimor- pholino derivatives as phosphatidylinositol-3-kinases α ( PI3Kα) inhibitors, a self-organizing molecular field anal- ysis (SOMFA) model has been established. The cross-validated correlation coefficient (q2), non-cross-validated correlation coefficient ( r2) and standard error of estimate (SEE) reached 0. 636, 0. 702 and 0. 581, respectively. The contribution coefficient of the shape and electrostatic potential reached 0. 7 and 0. 3, respectively. This model was validated by a group of compounds as test set. The predicted non-cross-validated correlation coefficient (r2ped) reached 0. 808. With its obvious statistical significance, this model may provide a way to develop novel dimorpho- lino derivatives as PI3Kα inhibitors.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2013年第3期223-227,共5页 Journal of China Pharmaceutical University
基金 教育部博士点新教师基金资助项目(No.20090181120113)~~
关键词 PI3Kα 三维定量构效关系 自组织分子场分析 phosphatidylinositol-3-kinases α three-dimensional quantitative-structure activity relationship self-organizing molecular field analysis
  • 相关文献

参考文献1

二级参考文献76

  • 1Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, et al. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 1999; 59: 4042-9.
  • 2Nakatsu N, Nakamura T, Yamazaki K, Sadahiro S, Makuuchi H, Kanno J, et al. Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines. Mol Pharmacol 2007;72: 1171-80.
  • 3Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002; 62: 1139-47.
  • 4YamoriT. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatfcs. Cancer Chemother Pharmacol 2003; 52 Suppl 1: S74-9.
  • 5Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6: 813-23.
  • 6Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
  • 7Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83: 757-66.
  • 8Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989; 81: 1088-92.
  • 9Kong D, Dan S, Yamazaki K, Yamori T. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur J Cancer 2010; 46: 1111- 21.
  • 10Naasani I, Seimiya H, Yamori T, Tsuruo T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 1999; 59: 4004-11.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部